Literature DB >> 313353

A controlled comparison of continuous intraarterial and intravenous infusions of vasopressin in hemorrhage from esophageal varices.

M Chojkier, R J Groszmann, C E Atterbury, S Bar-Meir, A T Blei, J Frankel, M G Glickman, J L Kniaz, R Schade, G J Taggart, H O Conn.   

Abstract

Infusions of intraarterial vasopressin (IAV) into the superior mesenteric artery have been shown to be effective in controlling hemorrhage from esophagogastric varices. Intravenous infusions of vasopressin (IVV), which can be initiated rapidly and require less sophisticated equipment and personnel, have also been reported to control variceal hemorrhage. We undertook a controlled clinical trial to compare these two routes of administration. Twenty-two cirrhotic patients with massive hemorrhage from varices were randomized to receive either IVV or IAV. Intraarterial vasopressin was begun at 0.1 U/min and increased progressively as needed to 0.2, 0.3, 0.4, and 0.5 U/min. Intravenous vasopressin was begun at 0.3 U/min and increased progressively as needed to 0.6, 0.9, 1.2, and 1.5 U/min. Hemorrhage was controlled in 5 of 10 episodes (50%) with IVV and in 6 of 12 episodes (50%) with IAV. Seven of the ten episodes treated with IVV (70%) ended fatally compared with 9 of 12 treated with IAV (75%). Side-effects and complications occurred with similar frequency in the two groups. The two routes of administration are equal in effects, side-effects, and complications. We recommend that IVV, which can be administered more easily, be given a brief therapeutic trial early in the management of hemorrhage from varices.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 313353

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  25 in total

Review 1.  Somatostatin in portal hypertension.

Authors:  J S Morgan; R J Groszmann
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

2.  Endoscopic removal of impacted Sengstaken-Blakemore tube.

Authors:  D K Bhasin; S A Zargar; M Mandal; M Goenka; R Singh
Journal:  Surg Endosc       Date:  1989       Impact factor: 4.584

Review 3.  Medical treatment of portal hypertension and oesophageal varices.

Authors:  P C Hayes; A N Shepherd; I A Bouchier
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-10

Review 4.  Management of gastrointestinal hemorrhage.

Authors:  R J Hilsden; E A Shaffer
Journal:  Can Fam Physician       Date:  1995-11       Impact factor: 3.275

5.  The effects of vasopressin on hepatic haemodynamics in the cirrhotic and non-cirrhotic rat.

Authors:  S A Jenkins; D W Day; B Mooney; P Devitt; J N Baxter; I Taylor; R Shields
Journal:  Langenbecks Arch Chir       Date:  1985

6.  Octreotide in variceal bleeding.

Authors:  A K Burroughs
Journal:  Gut       Date:  1994       Impact factor: 23.059

Review 7.  Why have controlled trials failed to demonstrate a benefit of esophagogastroduodenoscopy in acute upper gastrointestinal bleeding? A probability model analysis.

Authors:  R A Erickson; M E Glick
Journal:  Dig Dis Sci       Date:  1986-07       Impact factor: 3.199

8.  [Gastrointestinal hemorrhage].

Authors:  E H Farthmann; R Kirchner; R Salm; J Grups
Journal:  Langenbecks Arch Chir       Date:  1981

9.  Hemodynamic effects of vasopressin, alone and in combination with nitroprusside, in patients with liver cirrhosis and portal hypertension.

Authors:  P Mols; R Hallemans; M Van Kuyk; C Melot; P Lejeune; H Ham; F Vertongen; R Naeije
Journal:  Ann Surg       Date:  1984-02       Impact factor: 12.969

10.  Current place of vasopressin analogues in the treatment of septic shock.

Authors:  Christian Ertmer; Sebastian Rehberg; Andrea Morelli; Martin Westphal
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.